Traditional Chinese medicine compound for treating gastric cancer, medicine and application

Abstract

The traditional Chinese medicine compound for treating the gastric cancer is prepared from the following raw materials in parts by weight: 8 to 16 parts of radix rehmanniae praeparata, 8 to 16 parts of radix rehmanniae, 10 to 20 parts of radix paeoniae rubra, 8 to 16 parts of radix paeoniae alba, 8 to 16 parts of radix angelicae sinensis, 8 to 16 parts of radix codonopsis, 6 to 16 parts of radix bupleuri, 10 to 20 parts of rhizoma atractylodis macrocephalae stir-fried with bran, 15 to 25 parts of herba scutellariae barbatae, 10 to 20 parts of ochre, 4 to 8 parts of fructus jujubae and 8 to 16 parts of rhizoma chuanxiong. The traditional Chinese medicine composition is prepared from 20-40 parts of astragalus membranaceus, 15-25 parts of poria cocos, 6-15 parts of pericarpium citri reticulatae, 10-20 parts of duchesnea indica, 15-25 parts of roasted malt and 4-8 parts of honey-fried licorice root. The traditional Chinese medicine composition has the remarkable effects of strengthening the body resistance, resisting cancer, preventing relapse and metastasis, being definite in curative effect, reducing toxicity, improving the effect, improving the life quality of a patient and prolonging the life of the patient.

Description

Technical Field

[0001] The present invention relates to the technical field of Chinese medicine preparations, and in particular to a Chinese medicine compound for treating gastric cancer, a medicine and an application thereof. Background Art

[0002] Cancer is a major disease that seriously endangers people's health in the world. About a quarter of people die from diseases due to cancer. Among them, gastric cancer is one of the most common digestive tract malignancies, with a high incidence and poor prognosis.

[0003] Currently, surgical resection is the preferred treatment for gastric cancer, but due to the lack of typical early symptoms, most patients have already had distant metastasis when they seek medical treatment, and lose the opportunity for surgical treatment. In addition, chemotherapy is also a common treatment method, but due to the high toxicity of chemotherapy drugs, while killing tumor cells, they also non-selectively kill white blood cells, lymphocytes and other human immune cells, resulting in patients often suffering from infections due to low immune capacity, and patients have a large number of adverse reactions, and the course of treatment is long and the cost is high, which has great limitations in clinical use.

[0004] In recent years, traditional Chinese medicine has unique advantages in the treatment of gastric cancer. Natural medicines represented by traditional Chinese medicine have the characteristics of small toxic side effects, diverse targets, good tolerance, etc., and are increasingly valued in the treatment of tumors. However, the currently reported anti-gastric cancer drugs have a large dosage, a large number of impurities, a slow onset of action, and are also a burden on the stomach, which is not conducive to the cure of gastric cancer.

[0005] Therefore, it is necessary to research and develop a Chinese medicine compound for the treatment of gastric cancer based on the theory of traditional Chinese medicine, which has high safety, good anti-tumor effect, low dosage, good therapeutic effect on gastric cancer, and low adverse reactions. Summary of the invention

[0006] In view of the deficiencies in the prior art, the purpose of the present invention is to provide a Chinese herbal compound, medicine and application for treating gastric cancer which has obvious efficacy, no toxic side effects, can delay the progression of the disease and thus prolong the life of the patient.

[0007] To achieve the above object, the technical solution adopted by the present invention is as follows:

[0008] In a first aspect, the present invention provides a Chinese medicine compound for treating gastric cancer, the key of which is that it is composed of the following raw materials in parts by weight: 8-16 parts of Rehmannia root, 8-16 parts of Rehmannia root, 10-20 parts of red peony root, 8-16 parts of white peony root, 8-16 parts of Angelica sinensis, 8-16 parts of Codonopsis pilosula, 6-16 parts of Bupleurum chinense, 10-20 parts of stir-fried Atractylodes macrocephala, 15-25 parts of Scutellaria barbata, 10-20 parts of ochre, 4-8 parts of jujube, 8-16 parts of Chuanxiong, 20-40 parts of Astragalus, 15-25 parts of Poria, 6-15 parts of dried tangerine peel, 10-20 parts of Duchesnea sinensis, 15-25 parts of stir-fried malt, and 4-8 parts of roasted Licorice root.

[0009] Furthermore, the Chinese medicinal compound for treating gastric cancer is composed of the following raw materials in parts by weight: 10-14 parts of Rehmannia root, 10-14 parts of Rehmannia root, 12-18 parts of red peony root, 10-14 parts of white peony root, 9-15 parts of Angelica sinensis, 10-15 parts of Codonopsis pilosula, 8-12 parts of Bupleurum chinense, 12-17 parts of Atractylodes macrocephala with bran, 18-23 parts of Scutellaria barbata, 12-18 parts of ochre, 5-8 parts of jujube, 10-15 parts of Chuanxiong, 25-35 parts of Astragalus, 16-24 parts of Poria, 7-14 parts of dried tangerine peel, 12-16 parts of Duchesnea sinensis, 16-24 parts of roasted malt, and 4-8 parts of roasted liquorice.

[0010] Furthermore, the Chinese medicine compound for treating gastric cancer is composed of the following raw materials in parts by weight: 10 parts of Rehmannia root, 10 parts of Rehmannia root, 12 parts of red peony root, 10 parts of white peony root, 15 parts of Angelica sinensis, 15 parts of Codonopsis pilosula, 12 parts of Bupleurum chinense, 17 parts of stir-fried Atractylodes macrocephala, 23 parts of Scutellaria barbata, 18 parts of ochre, 5 parts of jujube, 10 parts of Chuanxiong, 25 parts of Astragalus, 16 parts of Poria, 7 parts of dried tangerine peel, 12 parts of Duchesnea sinensis, 16 parts of stir-fried malt, and 8 parts of roasted Licorice root.

[0011] Furthermore, the Chinese medicine compound for treating gastric cancer is composed of the following raw materials in parts by weight: 11 parts of Rehmannia root, 11 parts of Rehmannia root, 14 parts of red peony root, 10 parts of white peony root, 12 parts of Angelica sinensis, 12 parts of Codonopsis pilosula, 11 parts of Bupleurum chinense, 13 parts of stir-fried Atractylodes macrocephala, 22 parts of Scutellaria barbata, 15 parts of ochre, 7 parts of jujube, 3 parts of Chuanxiong, 28 parts of Astragalus, 22 parts of Poria, 10 parts of dried tangerine peel, 14 parts of Duchesnea sinensis, 19 parts of roasted malt, and 7 parts of roasted Licorice root.

[0012] Furthermore, the Chinese medicine compound for treating gastric cancer is composed of the following raw materials in parts by weight: 12 parts of Rehmannia root, 12 parts of Rehmannia root, 15 parts of red peony root, 12 parts of white peony root, 12 parts of Angelica sinensis, 12 parts of Codonopsis pilosula, 10 parts of Bupleurum chinense, 15 parts of stir-fried Atractylodes macrocephala, 20 parts of Scutellaria barbata, 15 parts of ochre, 6 parts of jujube, 12 parts of Chuanxiong, 30 parts of Astragalus, 20 parts of Poria, 10 parts of dried tangerine peel, 15 parts of Duchesnea sinensis, 20 parts of roasted malt, and 6 parts of roasted Licorice root.

[0013] Furthermore, the Chinese medicine compound for treating gastric cancer is composed of the following raw materials in parts by weight: 13 parts of Rehmannia root, 14 parts of Rehmannia root, 18 parts of red peony root, 13 parts of white peony root, 10 parts of Angelica sinensis, 14 parts of Codonopsis pilosula, 9 parts of Bupleurum chinense, 16 parts of stir-fried Atractylodes macrocephala, 20 parts of Scutellaria barbata, 13 parts of ochre, 7 parts of jujube, 14 parts of Chuanxiong, 32 parts of Astragalus, 22 parts of Poria, 13 parts of dried tangerine peel, 5 parts of Duchesnea sinensis, 22 parts of stir-fried malt, and 5 parts of roasted Licorice root.

[0014] Furthermore, the Chinese medicine compound for treating gastric cancer is composed of the following raw materials in parts by weight: 14 parts of Rehmannia root, 14 parts of Rehmannia root, 18 parts of red peony root, 14 parts of white peony root, 9 parts of Angelica sinensis, 9 parts of Codonopsis pilosula, 8 parts of Bupleurum chinense, 12 parts of stir-fried Atractylodes macrocephala, 18 parts of Scutellaria barbata, 12 parts of ochre, 8 parts of jujube, 15 parts of Chuanxiong, 35 parts of Astragalus, 24 parts of Poria, 14 parts of dried tangerine peel, 12 parts of Duchesnea sinensis, 16 parts of roasted malt, and 8 parts of roasted Licorice root.

[0015] In a second aspect, the present invention provides a drug for treating gastric cancer, wherein the active ingredients of the drug are prepared from the Chinese herbal compound described in the first aspect.

[0016] This Chinese medicine compound has a definite therapeutic effect on the treatment of gastric cancer, and can reduce the adverse reactions of surgery, radiotherapy and chemotherapy, improve the patient's quality of life and prolong survival, so it can be used to make drugs for the treatment of gastric cancer.

[0017] Furthermore, the medicine is in the form of capsules, tablets, oral liquid or granules.

[0018] In a third aspect, the present invention provides a use of the Chinese herbal compound as described in the first aspect in preparing a medicament for treating gastric cancer.

[0019] The pharmacological effects of each raw material in the present invention are as follows:

[0020] Rehmannia root: Cyclophosphamide administration to experimental mice can induce chromosome and micronucleus mutations. In the experiment, the use of Rehmannia root polysaccharide can significantly inhibit the mutation of mice. Rehmannia root inhibits cell mutation by reducing the exchange of monomers between mutant chromosomes. The water extract of Rehmannia root stimulates the mononuclear secretion of tumor necrosis factor in experimental mice, indicating that Rehmannia root has the pharmacological effect of inhibiting tumor cell activity and achieving anti-tumor effects.

[0021] Raw Rehmannia: The anti-tumor effect of Rehmannia polysaccharide, the main component of Raw Rehmannia, is mainly to affect the immune surveillance system of tumor-bearing animals, promote T lymphocyte activation, directly kill tumor cells, and produce a series of lymphokines to activate other effector cells, such as NK cells and B lymphocytes, to work together. The effect of Rehmannia polysaccharide on survival rate may be due to the influence of transfection reagents, or after high expression of NICD activates Notch signal, inducing cell apoptosis through the P53 apoptosis pathway.

[0022] Red peony root: The main chemical components of red peony root are terpenoids, tannins and flavonoids. Ren Weiyu conducted HPLC analysis on all the extracted parts of red peony root. The results showed that the effective chemical components of red peony root have good anti-tumor effect, and its anti-tumor activity of inhibiting ras mutation is the result of the combined action of many effective components, which also shows that the herb red peony root has good anti-tumor activity.

[0023] White peony root: The drug composition of white peony root is volatile oil, monoterpenoid glycosides, flavonoids, tannins and other substances, but modern research mainly focuses on paeoniflorin components, which are widely used in autoimmune diseases, tumors, and digestive tract diseases. Studies have shown that white peony total glucosides have a definite effect on relieving pain in visceral pain colic and cancer pain, and to a certain extent antagonize the tolerance of opioid analgesics. At the same time, white peony total glucosides can inhibit the growth of gastric cancer rats, induce apoptosis of tumor cells, and improve renal function damage caused by chemotherapy drugs. White peony glucosides inhibit the proliferation and migration of tumor cells by regulating the p38MAPK signaling pathway.

[0024] Angelica: Domestic and foreign scholars have used modern extraction, separation and content determination methods to study and find that one of its main components, Angelica polysaccharides, has certain anti-tumor pharmacological activity. Most studies believe that polysaccharide components can improve the body's immune function, which is the basis for its application in anti-tumor. Angelica polysaccharides can inhibit tumor proliferation and are natural inducers that induce tumor cell apoptosis or differentiation.

[0025] Codonopsis: This drug mainly contains acetylenes such as codonopsis acetylene alcohol and terpenoids such as oleanolic acid, and is widely used in various clinical departments. Studies have shown that Codonopsis can regulate biological processes such as tumor cell proliferation, apoptosis, migration, anoikis and angiogenesis, thereby effectively inhibiting the proliferation of gastric cancer tumor cells. Codonopsis polysaccharides mainly play an anti-cancer role by promoting NK cell immune activity and upregulating the expression of anti-tumor factors.

[0026] Bupleurum: It is currently believed that the main components of Bupleurum are Bupleurum volatile oil, triterpenoid saponins, flavonoids and other components. Bupleurum saponins have anti-tumor effects and inhibit the occurrence and development of various tumors. Modern research has confirmed that Bupleurum saponin-d has an up-regulating effect on the expression of tumor apoptosis genes, and the inhibitory effect of Bupleurum total saponins on gastric cancer cells is closely related to its dose. Bupleurum volatile oil has clear antipyretic, analgesic, anti-inflammatory and anticonvulsant effects.

[0027] Fried Atractylodes macrocephala with bran: It is a kind of tonic medicine with bitter, sweet and warm nature. It has the effects of replenishing qi and strengthening the spleen, drying dampness and promoting diuresis, stopping sweating and calming the fetus. It is mainly used for spleen and stomach qi deficiency, poor appetite and loose stools, abdominal pain, fatigue and other symptoms. Atractylodes macrocephala has the effect of replenishing qi and strengthening the spleen. It is often used in combination with ginseng, Poria cocos and other drugs to treat spleen deficiency; it is often used in combination with Citrus aurantium to treat spleen deficiency and stagnation, abdominal pain; it can be used in combination with cinnamon twig and Poria cocos to treat spleen deficiency and water retention, edema and difficulty urinating.

[0028] Scutellaria barbata: Scutellaria barbata flavonoids are the effective flavonoid ingredients extracted and separated from Scutellaria barbata. Lai Changwei conducted in vitro experiments to study the anti-tumor activity of Scutellaria barbata flavonoids. The results showed that the flavonoid components in Hedyotis diffusa and Scutellaria barbata were closely related to the anti-tumor efficacy. The flavonoid part was the main effective part that inhibited the killing of SGC-7901 and had a good anti-tumor effect.

[0029] Ochre: cold in nature, bitter in taste. Enters the liver meridian, heart meridian, lung meridian, and stomach meridian. It calms the liver and suppresses yang, calms the adverse qi, cools the blood and stops bleeding. Ochre can increase the number of white blood cells and cause an increase in the protein content of lung mitochondria and the activity of cytochrome C oxidase.

[0030] Jujube: The main chemical components of jujube are jujube polysaccharides and jujube proteins. Zhang Qing used the MTT method to study the effects of jujube neutral polysaccharide (JDP-N) on the secretion of tumor necrosis factor and its mRNA expression level in mouse macrophages. The study found that JDP-N has no direct effect on killing tumor cells, but can play an indirect anti-cancer role through immunomodulation and balancing the content of cytokines and inflammatory mediators.

[0031] Chuanxiong: The chemical components of this drug are mainly volatile oils, alkaloids, polysaccharides, etc., and it is widely used in clinical practice. Studies have shown that Chuanxiong can inhibit tumor cell proliferation, induce tumor cell apoptosis, inhibit the expression of oncogenes, improve blood hypercoagulability, resist tumor angiogenesis, improve hypoxic microenvironment, affect tumor cell invasion, migration and adhesion, enhance immune surveillance and immune regulation, and enhance the efficacy and reduce the toxicity of chemotherapy drugs, thereby preventing and treating the invasion and metastasis of malignant tumors and playing an anti-tumor role.

[0032] Astragalus: Astragalus’ anti-tumor effect mainly involves inhibiting the proliferation and migration of tumor cells. Astragaloside IV can inhibit the proliferation and migration of cervical cancer Hela cells and reversely regulate their proliferation and migration ability, which is related to affecting the expression of programmed death molecules PD-1 and ligand PD-L1. Astragalus polysaccharides not only enhance the body’s autophagy, but also can resist the autophagy of tumor cells, which further indicates the effectiveness of astragalus polysaccharides in anti-tumor.

[0033] Poria: Poria can scavenge free radicals and improve the specific cellular immune activity of mice, but has no significant effect on the specific humoral immunity of mice. It is generally believed that the main mechanism of Poria to enhance immune function is that the triterpenes and polysaccharides in Poria can improve immune function and regulate the body's immunity.

[0034] Tangerine peel: Tangerine peel has significant anti-tumor effects, and the basis of its efficacy is flavonoids, such as tangerine peel polymethoxyflavonoids and nobiletin. Tangerine peel polymethoxyflavonoids can directly inhibit tumor growth in vitro and in vivo. The anti-tumor effect may be through regulating the level of cytokines in the body, thereby affecting the expression of angiogenesis-related factors in tumor tissues and inhibiting tumor blood vessel growth, producing an anti-tumor effect; nobiletin can inhibit the proliferation of lung cancer cells in vitro and in vivo, and its mechanism of action may be related to changing the Bcl-2 / Bax ratio and initiating the Caspase cascade reaction.

[0035] Duchesnea: Duchesnea has significant anti-tumor activity. Experiments have shown that the polysaccharide components extracted from Duchesnea at a concentration of 200 mg / kg have a relatively clear anti-tumor activity on S180 sarcoma mice, with an inhibition rate of 63.5%. Duchesnea total phenol has a high anti-tumor activity, can directly act on tumor cells, enhance the secretion of B cell antibodies and T cell proliferation, and can also exert its anti-tumor effect in vivo by improving the body's cellular and humoral immunity.

[0036] Roasted malt: The important substance in roasted malt that plays the role of soothing the liver and strengthening the spleen and promoting lactation is B vitamins. When B vitamins are sufficient, they can relieve anxiety and tension. When they are deficient, fatigue and loss of appetite can occur. They can also reduce the body's ability to resist strain, weaken gastrointestinal motility, and reduce the secretion of digestive juices, resulting in symptoms such as indigestion, bad breath, constipation, and smelly stools. Lu Chuanbao's research found that malt is rich in vitamin B6, which is an important substance involved in maintaining human metabolism, especially having a greater impact on emotions and digestive functions.

[0037] Roasted Licorice: The confirmed pharmacological effects of licorice flavonoids include antioxidant, antispasmodic and antiasthmatic, anti-tumor, inhibition of bacterial growth, hypoglycemic, and hormone-like effects. Glycyrrhizic acid has a significant preventive effect on the occurrence of colon cancer by inhibiting the Ki-67 and NF-kB-p65 pathways. The licorice polysaccharides in roasted licorice can increase the spleen index and thymus index, which have immune functions, thereby improving the body's immunity.

[0038] The remarkable effects of the present invention are:

[0039] The invention provides a traditional Chinese medicine compound and medicine for treating gastric cancer. The medicine is prepared by compounding 18 kinds of traditional Chinese medicine materials, including astragalus, angelica, prepared rehmannia, white peony root, chuanxiong, codonopsis, bupleurum, tangerine peel, fried atractylodes macrocephala with bran, raw rehmannia, red peony root, ochre, tuckahoe, fried malt, indusia, scutellaria barbata, roasted licorice, and jujube. Astragalus and angelica are monarch medicines, prepared rehmannia, white peony root, chuanxiong, codonopsis, bupleurum, tangerine peel, fried atractylodes macrocephala with bran are ministerial medicines, raw rehmannia, red peony root, ochre, tuckahoe, fried malt, indusia, and scutellaria barbata are adjuvant medicines, and roasted licorice and jujube are guiding medicines. Syndrome differentiation is combined with disease differentiation. According to the etiology, pathogenesis and pathological characteristics of gastric cancer, the medicine is reasonably compatible to achieve the best results. The medicine can not only strengthen the body and fight cancer, but also prevent recurrence and metastasis. The medicine has definite curative effect, can reduce toxicity and increase efficacy, improve the quality of life of patients, and prolong the life of patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 It is a schematic diagram of the intersection of the Chinese herbal compound of the present invention and gastric cancer-related targets;

[0041] Figure 2 Schematic diagram of the core target screened by the present invention;

[0042] Figure 3 This is a schematic diagram of the structure of the core targets screened by the present invention being brought into KEGG for analysis;

[0043] Figure 4 It is a schematic diagram of the structure of the core targets screened by the present invention for related pathway analysis;

[0044] Figure 5 It is a schematic diagram of the CCK-8 values ​​of each group of cells detected during in vitro culture of the present invention;

[0045] Figure 6 It is a schematic diagram of the experimental results of the cell scratch experiment performed by the present invention;

[0046] Figure 7 It is a schematic diagram of the experimental results of the transwell experiment performed by the present invention;

[0047] Figure 8 It is a schematic diagram of the experimental results of the drug-cell apoptosis experiment conducted by the present invention;

[0048] Fig. 9 It is a schematic diagram of the experimental results of the WB experiment performed by the present invention. DETAILED DESCRIPTION

[0049] The specific implementation manner and working principle of the present invention are further described in detail below with reference to the accompanying drawings.

[0050] Embodiment 1:

[0051] The embodiment of the present invention provides a traditional Chinese medicine compound for treating gastric cancer, which is composed of the following raw materials in parts by weight: 10 parts of Rehmannia root, 10 parts of Rehmannia root, 12 parts of red peony root, 10 parts of white peony root, 15 parts of Angelica sinensis, 15 parts of Codonopsis pilosula, 12 parts of Bupleurum chinense, 17 parts of bran-fried Atractylodes macrocephala, 23 parts of Scutellaria barbata, 18 parts of ochre, 5 parts of jujube, 10 parts of Chuanxiong, 25 parts of Astragalus, 16 parts of Poria, 7 parts of dried tangerine peel, 12 parts of Duchesnea sinensis, 16 parts of roasted malt, and 8 parts of roasted Licorice root.

[0052] The embodiment of the present invention also provides a drug for treating gastric cancer, wherein the active ingredients of the drug are prepared from the above-mentioned Chinese medicine compound, and the drug can be in the form of capsules, tablets, oral liquids or granules, as well as other forms of preparations such as drops.

[0053] Embodiment 2:

[0054] The embodiment of the present invention provides a traditional Chinese medicine compound for treating gastric cancer, which is composed of the following raw materials in parts by weight: 11 parts of Rehmannia root, 11 parts of Rehmannia root, 14 parts of red peony root, 10 parts of white peony root, 12 parts of Angelica sinensis, 12 parts of Codonopsis pilosula, 11 parts of Bupleurum chinense, 13 parts of bran-fried Atractylodes macrocephala, 22 parts of Scutellaria barbata, 15 parts of ochre, 7 parts of jujube, 3 parts of Chuanxiong, 28 parts of Astragalus, 22 parts of Poria, 10 parts of dried tangerine peel, 14 parts of Duchesnea sinensis, 19 parts of roasted malt, and 7 parts of roasted Licorice root.

[0055] The embodiment of the present invention also provides a drug for treating gastric cancer, wherein the active ingredients of the drug are prepared from the above-mentioned Chinese medicine compound, and the drug can be in the form of capsules, tablets, oral liquids or granules, as well as other forms of preparations such as drops.

[0056] Embodiment 3:

[0057] The embodiment of the present invention provides a traditional Chinese medicine compound for treating gastric cancer, comprising 12 parts of Rehmannia root, 12 parts of Rehmannia root, 15 parts of red peony root, 12 parts of white peony root, 12 parts of Angelica sinensis, 12 parts of Codonopsis pilosula, 10 parts of Bupleurum chinense, 15 parts of fried Atractylodes macrocephala, 20 parts of Scutellaria barbata, 15 parts of ochre, 6 parts of jujube, 12 parts of Chuanxiong, 30 parts of Astragalus membranaceus, 20 parts of Poria cocos, 10 parts of dried tangerine peel, 15 parts of Duchesnea indica, 20 parts of fried malt, and 6 parts of roasted Licorice root.

[0058] The embodiment of the present invention also provides a drug for treating gastric cancer, wherein the active ingredients of the drug are prepared from the above-mentioned Chinese medicine compound, and the drug can be in the form of capsules, tablets, oral liquids or granules, as well as other forms of preparations such as drops.

[0059] Embodiment 4:

[0060] The embodiment of the present invention provides a traditional Chinese medicine compound for treating gastric cancer, which is composed of the following raw materials in parts by weight: 13 parts of Rehmannia root, 14 parts of Rehmannia root, 18 parts of red peony root, 13 parts of white peony root, 10 parts of Angelica sinensis, 14 parts of Codonopsis pilosula, 9 parts of Bupleurum chinense, 16 parts of bran-fried Atractylodes macrocephala, 20 parts of Scutellaria barbata, 13 parts of ochre, 7 parts of jujube, 14 parts of Chuanxiong, 32 parts of Astragalus, 22 parts of Poria, 13 parts of dried tangerine peel, 5 parts of Duchesnea sinensis, 22 parts of roasted malt, and 5 parts of roasted Licorice root.

[0061] The embodiment of the present invention also provides a drug for treating gastric cancer, wherein the active ingredients of the drug are prepared from the above-mentioned Chinese medicine compound, and the drug can be in the form of capsules, tablets, oral liquids or granules, as well as other forms of preparations such as drops.

[0062] Embodiment 5:

[0063] The embodiment of the present invention provides a traditional Chinese medicine compound for treating gastric cancer, which is composed of the following raw materials in parts by weight: 14 parts of Rehmannia root, 14 parts of Rehmannia root, 18 parts of red peony root, 14 parts of white peony root, 9 parts of Angelica sinensis, 9 parts of Codonopsis pilosula, 8 parts of Bupleurum chinense, 12 parts of fried Atractylodes macrocephala, 18 parts of Scutellaria barbata, 12 parts of ochre, 8 parts of jujube, 15 parts of Chuanxiong, 35 parts of Astragalus, 24 parts of Poria, 14 parts of dried tangerine peel, 12 parts of Duchesnea sinensis, 16 parts of fried malt, and 8 parts of roasted Licorice root.

[0064] The embodiment of the present invention also provides a drug for treating gastric cancer, wherein the active ingredients of the drug are prepared from the above-mentioned Chinese medicine compound, and the drug can be in the form of capsules, tablets, oral liquids or granules, as well as other forms of preparations such as drops.

[0065] In order to prove the efficacy of each embodiment of the present invention, the inventors of the present application firstly carried out network pharmacology analysis, summarized the effective ingredients in a single Chinese medicine, and corresponded the targets of the corresponding ingredients for treating gastric cancer, and concluded that the Chinese medicine compound or drug of the present invention is an effective way to treat gastric cancer, related pathways and other molecular mechanisms. The specific progress is as follows:

[0066] 1) The intersection of the active ingredients in the Chinese herbal compound or drug of the present invention and gastric cancer-related targets was taken, and 235 intersection targets were found, as follows: Figure 1 As shown;

[0067] 2) The intersection targets were excluded and screened, and the top 20 were finally selected as the core targets for the treatment of gastric cancer, such as Figure 2 As shown;

[0068] 3) All the selected core targets were brought into KEGG for analysis to obtain their BP, CC, and MF values, as follows: Figure 3 As shown;

[0069] 4) All the selected core targets were analyzed for relevant pathways. The analysis results are as follows Figure 4 As shown;

[0070] 5) In vitro experiments

[0071] ① The Chinese medicine compound or medicine of the present invention is decocted, and the surface area of ​​the stomach of humans and animals is calculated according to the "Experimental Animal Science" and the Chinese medicine is gavaged into SD rats for 7 days, and then the intercardiac blood is collected to prepare the drug serum;

[0072] ② Use the drug-containing serum to prepare complete culture medium, select MKN-45 cells, intervene with the prepared drug-containing serum, culture in a constant temperature box for 24 hours, and use the CCK-8 method to detect the CCK-8 value of each group of MKN-45 cells. The test results are as follows: Figure 5 As shown;

[0073] ③ According to the test results, three groups of cells were selected to form a blank group, a positive group, and a Chinese medicine group. Cell scratch experiments and transwell experiments were performed to detect the invasion and migration of HGC-27 cells. The results were as follows: Figure 6 and Figure 7 As shown;

[0074] ④ Flow cytometry was used to detect cell apoptosis and cell cycle. The test results were as follows: Figure 8 As shown, Figure 8 (a) is the blank group, Figure 8 (b) is the positive group, Figure 8 (c) Chinese medicine group;

[0075] ⑤WB experiments were used to detect the protein expression levels of BCL-2, SFRP1, GSK3-β, vimentin, MMP-7, β-catenin, Cyclin D1, and c-myc. The results of BCL-2 were as follows: Fig. 9 As shown in (a), the detection results of GSK3-β are as follows Fig. 9 (b) shows the detection results of vimentin. Fig. 9 (c) as shown.

[0076] It can be seen from the above experiments that the Chinese herbal compound or medicine of the present invention can effectively inhibit the growth of gastric cancer cells.

[0077] In summary, the present invention provides a traditional Chinese medicine compound and medicine for treating gastric cancer, which are prepared by compounding 18 kinds of traditional Chinese medicine materials including astragalus, angelica, cooked rehmannia, white peony root, chuanxiong, codonopsis, bupleurum, tangerine peel, fried atractylodes macrocephala, raw rehmannia, red peony root, ochre, tuckahoe, fried malt, duxole, scutellaria barbata, roasted licorice, and jujube, and astragalus and angelica are monarch medicines, cooked rehmannia, white peony root, chuanxiong, codonopsis, bupleurum, tangerine peel, fried atractylodes macrocephala as ministerial medicines, raw rehmannia, red peony root, ochre, tuckahoe, fried malt, duxole, and scutellaria barbata as adjuvant medicines, and roasted licorice and jujube as guiding medicines, combining syndrome differentiation with disease differentiation, and according to the etiology, pathogenesis and pathological characteristics of gastric cancer, through reasonable compatibility, they complement each other, can not only strengthen the body to fight cancer, but also prevent recurrence and metastasis, have definite efficacy, can also reduce toxicity and increase efficacy, improve the quality of life of patients, and prolong the life of patients.

[0078] The technical solution provided by the present invention is described in detail above. Specific examples are used herein to illustrate the principles and implementation methods of the present invention. The description of the above embodiments is only used to help understand the method of the present invention and its core idea. It should be pointed out that for ordinary technicians in this technical field, without departing from the principle of the present invention, the present invention can also be improved and modified in a number of ways, and these improvements and modifications also fall within the scope of protection of the claims of the present invention.

Claims

1. A Chinese medicinal compound for treating gastric cancer, characterized in that: The invention is composed of the following raw materials in parts by weight: 8-16 parts of Rehmannia root, 8-16 parts of Rehmannia root, 10-20 parts of red peony root, 8-16 parts of white peony root, 8-16 parts of Chinese angelica root, 8-16 parts of Codonopsis pilosula, 6-16 parts of Bupleurum root, 10-20 parts of fried Atractylodes macrocephala with bran, 15-25 parts of Scutellaria barbata, 10-20 parts of ochre, 4-8 parts of jujube, 8-16 parts of Chuanxiong, 20-40 parts of Astragalus, 15-25 parts of Poria, 6-15 parts of dried tangerine peel, 10-20 parts of Duchesnea sinensis, 15-25 parts of fried malt and 4-8 parts of roasted liquorice.

2. The Chinese medicinal composition for treating gastric cancer according to claim 1, characterized in that: The invention is composed of the following raw materials in parts by weight: 10-14 parts of Rehmannia root, 10-14 parts of Rehmannia root, 12-18 parts of red peony root, 10-14 parts of white peony root, 9-15 parts of Angelica sinensis, 10-15 parts of Codonopsis pilosula, 8-12 parts of Bupleurum root, 12-17 parts of Atractylodes macrocephala with bran, 18-23 parts of Scutellaria barbata, 12-18 parts of ochre, 5-8 parts of jujube, 10-15 parts of Chuanxiong, 25-35 parts of Astragalus, 16-24 parts of Poria, 7-14 parts of dried tangerine peel, 12-16 parts of Duchesnea indica, 16-24 parts of roasted malt and 4-8 parts of roasted liquorice.

3. The Chinese medicinal compound for treating gastric cancer according to claim 2, characterized in that: The invention is composed of the following raw materials in parts by weight: 10 parts of Rehmannia root, 10 parts of Rehmannia root, 12 parts of red peony root, 10 parts of white peony root, 15 parts of Angelica sinensis, 15 parts of Codonopsis pilosula, 12 parts of Bupleurum chinense, 17 parts of fried Atractylodes macrocephala with bran, 23 parts of Scutellaria barbata, 18 parts of ochre, 5 parts of jujube, 10 parts of Chuanxiong, 25 parts of Astragalus, 16 parts of Poria, 7 parts of dried tangerine peel, 12 parts of Duchesnea indica, 16 parts of fried malt and 8 parts of roasted Licorice root.

4. The Chinese medicinal compound for treating gastric cancer according to claim 2, characterized in that: The invention is composed of the following raw materials in parts by weight: 11 parts of Rehmannia root, 11 parts of Rehmannia root, 14 parts of red peony root, 10 parts of white peony root, 12 parts of Angelica sinensis, 12 parts of Codonopsis pilosula, 11 parts of Bupleurum root, 13 parts of fried Atractylodes macrocephala with bran, 22 parts of Scutellaria barbata, 15 parts of ochre, 7 parts of jujube, 3 parts of Ligusticum chuanxiong, 28 parts of Astragalus, 22 parts of Poria, 10 parts of dried tangerine peel, 14 parts of Duchesnea sinensis, 19 parts of fried malt and 7 parts of roasted Licorice root.

5. The Chinese medicinal compound for treating gastric cancer according to claim 2, characterized in that: The invention is composed of the following raw materials in parts by weight: 12 parts of Rehmannia root, 12 parts of Rehmannia root, 15 parts of red peony root, 12 parts of white peony root, 12 parts of Angelica sinensis, 12 parts of Codonopsis pilosula, 10 parts of Bupleurum chinense, 15 parts of fried Atractylodes macrocephala with bran, 20 parts of Scutellaria barbata, 15 parts of ochre, 6 parts of jujube, 12 parts of Ligusticum chuanxiong, 30 parts of Astragalus membranaceus, 20 parts of Poria cocos, 10 parts of dried tangerine peel, 15 parts of Duchesnea indica, 20 parts of roasted malt and 6 parts of roasted Licorice root.

6. The Chinese medicinal compound for treating gastric cancer according to claim 2, characterized in that: The invention is composed of the following raw materials in parts by weight: 13 parts of Rehmannia root, 14 parts of Rehmannia root, 18 parts of red peony root, 13 parts of white peony root, 10 parts of Angelica sinensis, 14 parts of Codonopsis pilosula, 9 parts of Bupleurum chinense, 16 parts of stir-fried Atractylodes macrocephala, 20 parts of Scutellaria barbata, 13 parts of ochre, 7 parts of jujube, 14 parts of Ligusticum chuanxiong, 32 parts of Astragalus membranaceus, 22 parts of Poria cocos, 13 parts of dried tangerine peel, 5 parts of Duchesnea indica, 22 parts of stir-fried malt and 5 parts of roasted Licorice root.

7. The Chinese medicinal compound for treating gastric cancer according to claim 2, characterized in that: The invention is composed of the following raw materials in parts by weight: 14 parts of Rehmannia root, 14 parts of Rehmannia root, 18 parts of red peony root, 14 parts of white peony root, 9 parts of Angelica sinensis, 9 parts of Codonopsis pilosula, 8 parts of Bupleurum chinense, 12 parts of fried Atractylodes macrocephala with bran, 18 parts of Scutellaria barbata, 12 parts of ochre, 8 parts of jujube, 15 parts of Ligusticum chuanxiong, 35 parts of Astragalus membranaceus, 24 parts of Poria, 14 parts of dried tangerine peel, 12 parts of Duchesnea indica, 16 parts of fried malt and 8 parts of roasted Licorice root.

8. A drug for treating gastric cancer, characterized in that: The active ingredients of the medicine are prepared from the Chinese medicinal compound according to any one of claims 1 to 7.

9. The drug for treating gastric cancer according to claim 8, characterized in that: The medicine is in the form of capsules, tablets, oral liquid or granules.

10. Use of the Chinese medicinal compound according to any one of claims 1 to 7 in preparing a medicament for treating gastric cancer.

Images